Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Everolimus for Patients With Relapsed/Refractory Germ Cell Cancer (RADIT)

This study has been completed.
Information provided by (Responsible Party):
Hannover Medical School Identifier:
First received: November 16, 2010
Last updated: February 24, 2015
Last verified: February 2015
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: March 2014
  Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)